Suppr超能文献

急性血栓性血小板减少性紫癜中高分子量激肽原的蛋白水解降解

Proteolytic degradation of high molecular weight kininogen in acute thrombotic thrombocytopenic purpura.

作者信息

Pavord S, Kelton J G, Warner M N, Moore J C, Warkentin T E, Hayward C P

机构信息

Department of Medicine and Pathology, McMaster University, and the Hamilton Health Sciences Corporation, Ontario, Canada.

出版信息

Br J Haematol. 1997 Jun;97(4):762-7. doi: 10.1046/j.1365-2141.1997.1282947.x.

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by thrombocytopenia and schistocytic haemolytic anaemia. The majority of patients have normal coagulation parameters including the activated partial thromboplastin time (APTT). An intracellular cysteine protease, calpain, has been found in the plasma of many patients with acute TTP, and we hypothesize that it participates in the pathogenesis of the disorder. However, certain aspects of the disorder remain unresolved. For example, high molecular weight kininogen (HK) is one of the primary plasma inhibitors of calpain, and it also can act as a substrate for calpain. Consequently, one might anticipate that the HK could be defective or altered in TTP. In this report we describe the analysis of HK in plasma from live patients with acute TTP and following recovery. The HK was studied immunogenically and functionally. We observed that the HK in plasma samples from patients with acute TTP was proteolysed. This degradation was not observed in remission samples from the same patients. However, both acute and remission TTP samples had normal HK coagulant activity (acute samples, x = 0.84 +/- 0.26 U/ml; remission samples, x = 0.89 +/- 0.21 U/ml; control samples, x = 0.87 +/- 0.05 U/ml). Although the TTP plasmas were able to inhibit calpain activity, less inhibition activity was found in the acute samples (acute: mean inhibition 71 +/- 2.4%; remission: mean 92 +/- 2.1%; control samples: mean 93 +/- 5.4%; P < 0.001). Normal HK treated with calpain also had reduced calpain inhibition capacity (mean 58%). This study suggests that although HK is proteolysed during acute TTP, the proteolysis occurs without a major loss in the coagulation function or depletion of the protease inhibitory activity of HK.

摘要

血栓性血小板减少性紫癜(TTP)是一种以血小板减少和碎裂性溶血性贫血为特征的疾病。大多数患者的凝血参数正常,包括活化部分凝血活酶时间(APTT)。在许多急性TTP患者的血浆中发现了一种细胞内半胱氨酸蛋白酶——钙蛋白酶,我们推测它参与了该疾病的发病机制。然而,该疾病的某些方面仍未得到解决。例如,高分子量激肽原(HK)是钙蛋白酶的主要血浆抑制剂之一,它也可以作为钙蛋白酶的底物。因此,人们可能预期HK在TTP中会有缺陷或改变。在本报告中,我们描述了对急性TTP患者存活期及康复后血浆中HK的分析。对HK进行了免疫和功能研究。我们观察到急性TTP患者血浆样本中的HK被蛋白水解。在同一患者的缓解期样本中未观察到这种降解。然而,急性和缓解期TTP样本的HK凝血活性均正常(急性样本,x = 0.84 +/- 0.26 U/ml;缓解期样本,x = 0.89 +/- 0.21 U/ml;对照样本,x = 0.87 +/- 0.05 U/ml)。虽然TTP血浆能够抑制钙蛋白酶活性,但在急性样本中发现的抑制活性较低(急性:平均抑制率71 +/- 2.4%;缓解期:平均92 +/- 2.1%;对照样本:平均93 +/- 5.4%;P < 0.001)。用钙蛋白酶处理的正常HK也具有降低的钙蛋白酶抑制能力(平均58%)。这项研究表明,虽然HK在急性TTP期间被蛋白水解,但这种蛋白水解发生时,HK的凝血功能没有重大损失,其蛋白酶抑制活性也没有耗尽。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验